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B lymphocytes proliferate in response to ex-
trinsic antigen and help from T cells, but enter 
a quiescent memory state once antigen is re-
moved (1). However, if antigen is not removed, 
B cells could chronically proliferate, accumulating 
genetic changes in the process, and ultimately 
become malignantly transformed. Consistent 
with such an idea, B lymphoma development 
has been associated with chronic infections caused 
by EBV, hepatitis C, and Helicobacter pylori, 
autoimmune diseases like rheumatoid arthritis, 
Sjögren’s syndrome, and systemic lupus erythe-
matosus, and allotransplantation as well as graft 
versus host disease (for review see reference 2, 3). 
However, most B lymphomas arise in the ab-
sence of any known antigenic exposure. Thus, 
novel sources of antigen relevant to lymphom-
agenesis should be sought.
Further suggesting a role for chronic anti-
genic stimulation, human follicular (2, 4, 5) and 
diff  use large B cell lymphomas (2, 6) are often 
infi  ltrated with T cells. However, the specifi  cities 
and function of these T cells are unknown. Thus, 
it is unclear whether the infi  ltrating T cells attack 
the lymphoma cells, are inert neutral  bystanders, 
or actually support lymphoma growth through 
unknown mechanisms. We have inves  tigated if 
T cells with a defi  ned specifi  city toward a clonally 
restricted self-antigen, constitutively produced by 
B cells, could induce B lymphoma development.
B cells express a receptor for antigen (B cell 
receptor [BCR]) with variable regions generated 
by rearrangement of V(D)J gene segments and 
somatic hypermutation. These genetic mecha-
nisms generate variable regions with unique anti-
genic determinants, called idiotopes, which mark 
each clone of B cells. Id is expressed on surface Ig 
of B cells and may be recognized by antibodies 
(7). In addition, it has been shown that both 
B lymphoma (8, 9) and B cells (10) partially de-
grade their endogenous BCR and display Id pep-
tides on their MHC class II   molecules to CD4+ 
T cells (reference 11; Fig. 1 A). Supporting evi-
dence comes from the fi  nding that Ig-derived 
peptides, including Id peptides, can be eluted 
from class II molecules of B lymphoma cells and 
EBV transformed B cells (12–15).
Such constitutive B cell presentation of endog-
enous Id peptides should be of no consequence 
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if T cells are uniformly tolerant. However, although T cells 
are indeed unresponsive to abundant germline-encoded Id 
peptides shared among large numbers of B cells and serum 
Ig molecules, they can readily respond to rare Id peptides 
derived from unique N regions or somatic mutations ex-
pressed by very few B cells (16–18). However, the TCR 
repertoire for a particular rare Id peptide was shown to be 
  severely limited (19), suggesting a rather low frequency of 
Id-specifi  c T cells.
Based on the evidence presented here, it was suggested 
that infrequent B cells could directly interact with infrequent 
Id-specifi  c T cells in a process called Id-driven T–B collabo-
ration (20). However, the rarity of matching B and T cells made 
it diffi   cult to prove that such interactions actually occurred 
in vivo. This problem was circumvented by making paired 
Id+Ig L chain transgenic mice and Id-specifi  c TCR-transgenic 
mice, which harbor high frequencies of Id+ B cells and Id-
specifi  c CD4+ T cells, respectively (21, 22). By transferring 
B and T cells between such paired strains of mice, it was 
  demonstrated in two independent models by us (10, 23) and 
others (24) that cognate Id-driven T–B collaboration occurred 
in vivo. Moreover, such Id-driven T–B collaboration resulted 
in induction of autoantibodies (23, 24). In the course of these 
experiments, we incidentally observed that Id+ λ2315 L chain 
transgenic mice, which had repetitiously received Id-specifi  c 
Th2 cells, developed frank lymphomas after a latency period 
of >5 mo. These results suggested that Id peptides could 
  represent a source of diversifi  ed antigen for stimulation of Th2 
cells, chronic cognate B cell help, and lymphomagenesis.
RESULTS
Id-specifi  c Th2 cells induce tumors in Id+ mice
Id+ B cells from Id+ mice display a BCR with a trangenic Id+ 
λ2315 Ig L chain (21). The amino acids 91–101 of this chain 
correspond to a CDR3 Id peptide that is exceedingly rare in 
normal mice caused by somatic mutations in positions 94–96 
(Tyr94Ser95Thr96® Phe94Arg95Asn96). The λ2315 L chain is 
constitutively processed by the Id+ B cells, and the Id peptide 
is presented on MHC class II molecules (I-Ed) (8–10) to 
Id-specifi  c CD4+ T cells from TCR transgenic mice (reference 
22; Fig. 1 A). 
Id+ mice were injected i.v. with fi  ve million cultured Id-
  specifi  c Th2 cells, derived from TCR transgenic mice, every 
10th day for 80 d. About 150 d later, such mice started to 
  develop distended abdomens. Within the next 120 d, more 
than half of the mice had developed massive splenomegaly 
(Figs. 1 B and 2 A), greatly enlarged lymph nodes (Fig. 2 B), 
and often had aff  ection of other organs such as livers (Fig. 2 B). 
Later experiments demonstrated that only two injections of 
Id-specifi  c Th2 cells, spaced 10 d apart, suffi   ced for tumor 
  development (Fig. 1 C). Tumor development was dependent 
on the Id specifi  city of the Th2 cells because injections of 
  ovalbumin-specifi  c Th2 cells failed to induce tumors (Fig. 1 B). 
Old BALB/c mice are predisposed to develop lymphoma; how-
ever, none were detected in controls within the time frame of 
the experiments (Fig. 1 B). 
B cell lymphomas were of the large cell type and expressed 
markers suggesting a relationship to the marginal zone 
B cell lineage
The normal architecture of the involved tissues was most of-
ten eff  aced by confl  uent areas of large IgM+IgD+B220+ lym-
phoma cells that mostly had round to ovoid nuclei, distinct 
nucleoli, and moderate to large amounts of eosinophilic cyto-
plasm. In cases of lesser disease, only the white pulp was in-
volved (Fig. 3 A). Mitotic fi  gures were observed (Fig. 2 C 
and Fig. S1, available at http://www.jem.org/cgi/content/
full/jem.20061220/DC1). The lymphomas contained con-
siderable numbers of small, dense lymphocyte-like cells (Fig. 
2 C) that stained as CD3+ T cells (Fig. 2 D). This histopatho-
logical examination was consistent with B cell lymphomas of 
the large type with infi  ltration of T cells (25).
To remove any confounding eff  ects of normal B cells, 
lymphomatous spleen cells were transferred into RAG2−/− 
recipients that developed lymphomas within 6–8 wk. The 
lymphoma cells lacked the follicular B cell marker CD23, 
the germinal center marker BCL-6 (2), as well as the B1 cell 
marker CD5 (Fig. 3 A and Fig. S2, available at http://www.jem
.org/cgi/content/full/jem.20061220/DC1). They expressed 
surface markers suggestive of a relationship to the marginal 
zone lineage (CD23−CD21/35Hi CD1dHiCD38HiCD9+IgMHi; 
Figure 1.  Id+ mice repetitively injected with Id-specifi  c Th2 cells 
develop lymphoma. (A) Experimental model. (left) Id+ B cells from Id+ 
mice (17) display a transgenic L chain (λ2315) with a rare CDR3 Id 
  peptide (circle). The L chain is processed and the Id peptide is presented 
on MHC class II molecules (I-Ed) to Id-specifi  c CD4+ T cells from TCR 
transgenic mice. (middle) It was hypothesized that Id-specifi  c Th2 cells 
might induce chronic proliferation of Id+ B cells, accumulation of 
  genetic changes, and, fi  nally, B lymphoma development (right). (B) Develop-
ment of abdominal tumors. Id-specifi  c Th2 cells (5 × 106) generated 
in vitro from TCR transgenic mice were injected eight times, spaced 
10 d apart (arrows) into Id+ mice (Id-Th2®Id+) or Id− littermates 
(Id-Th2®Id−). As a control, ovalbumin-specifi  c Th2 cells from DO.11.10 
TCR transgenic mice were injected into Id+ mice (Ova-Th2®Id+). (C) Number 
of injections of Id-specifi  c Th2 cells needed for lymphoma development 
(3–11 mice/group).JEM VOL. 204, May 14, 2007  1183
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Fig. 3, A and B; and Fig. S2). An equivalent phenotype was found 
in the lymphoma originator mice (Fig. S2 and not depicted). 
The lymphoma phenotype was, however, not completely 
compatible with the marginal zone B cell subset because: 
(a) about half the lymphomas expressed low levels of the 
AA4.1 marker suggestive of a transitional B cell origin (Fig. 3 C). 
(b) Unlike marginal zone B cells, the lymphoma most often ex-
pressed normal amounts of IgD (Fig. 3 B and Fig. S2). (c) Unlike 
the previously described mouse marginal zone lymphomas 
(25–27), the present lymphomas were consistently found in 
extranodal sites, lymph nodes, and the bone marrow (Figs. 2 B, 
3 D, S2, and S3, available at http://www.jem.org/cgi/content/
full/jem.20061220/DC1; and not depicted). (d) No anatomical 
relationship was found to the marginal zone; however, at the 
time of analysis extensive tumors may have eff  aced the splenic 
architecture. (e) About half of the lymphomas had cells that 
expressed CD138, especially in the liver and after transfers, 
suggesting a degree of plasmacytoid diff  erentiation with time 
(Figs. 2 E and 3 D). Consistent with this, lymphomas were 
also positive for the interferon regulatory factor 4 (IRF-4) 
marker (Fig. 2 E), suggestive of some plasmacytoid diff  eren-
tiation. However, the lymphomas lacked a plasma cell pheno-
type because they secreted little Ig in vivo (unpublished data) 
and displayed high levels of surface Ig and MHC class II (see 
below and Fig. 3 G).
The lymphomas were responsive to IL-3 and expressed 
the IL-3 receptor
A panel of cytokines was added to lymphoma cells ex vivo 
to augment growth. Surprisingly, IL-3 resulted in 20× increase 
in lymphoma proliferation. Consistent with this fi  nding, 
nearly all lymphoma expresses the α (CD123) and β (CD131) 
chains of the IL-3 receptor (Fig. 3, E and F). To the best of 
our knowledge, expression of the IL-3 receptor has not been 
characterized in the marginal zone B cell compartment. We 
therefore investigated this issue and found that the IL-3 receptor 
was expressed on most marginal zone B cell precursors, but 
less on mature marginal zone B cells (Fig. S4, available at 
http://www.jem.org/cgi/content/full/jem.20061220/DC1). In 
conclusion, the functional IL-3 responsiveness, the IL-3 receptor 
expression of lymphoma cells, and the phenotype described in 
the preceding section point to a relationship with marginal 
zone precursor B cells.
Lymphoma cells were selected for expression of high levels 
of Id+ L chain, MHC class II, and costimulatory molecules
Strikingly, the B lymphoma cells had a phenotype appro  priate 
for potent interaction with T cells. They expressed high levels 
of MHC class II as well as costimulatory CD80/CD86 mole-
cules, both of which are important for effi   cient stimulation of 
CD4+ T cells (Fig. 3 G). They also strongly expressed the 
relevant antigen, the λ2 Id+ L chain (Figs. 2 F and 3 G). In 
striking contrast, B cells of age -matched Id+ mice expressed 
mainly κ, and little λ2, caused by leakiness of allelic exclusion 
with age (reference 21; Fig. 3 G). The induction of high λ2 
Id+ L chain expression required Id specifi  city of Th2 cells 
because injection of Th2 cells with an irrelevant specifi  city 
(ovalbumin) failed to increase λ2 expression (Fig. 3 H). These 
results indicate that injection of Id-specifi  c Th2 cells selectively 
induced lymphoma cells with a high stimulatory capacity 
for the injected T cells. Conversely, because lymphoma cells 
displayed high levels of CD40 (Fig. 3 G), they should be 
  es  pecially receptive to help from activated T cells that are known 
to express CD40L (1).
Figure 2.  Id+ diffuse large B cell lymphomas are infi  ltrated with 
Id-specifi  c T cells. (A) Lymphomatous spleen of an Id-Th2®Id+ mouse 
(top) compared with spleen from an Ova-Th2®Id+ mouse (bottom). 
(B) Photo of enlarged mesenteric LN in an Id-Th2®Id+ mouse with lym-
phoma (left). The circled asterisk indicates the normal size of a mesenteric 
LN in an Ova-Th2®Id+ mouse. (right) Liver from Id-Th2®Id+ mouse. 
Arrows indicate tumor nodules. (C) Low and high power magnifi  cation 
(hematoxylin and eosin) of lymphomatous spleen. (D) Lymphoma of the 
liver with infi  ltrating CD3+ T cells (brown). (E) Spleen lymphoma were 
B220+, IRF-4/MUM1+, and CD138+ (in about half of the mice) and were 
IgM+IgD+. In the rightmost immunofl  uorescence picture, DAPI stains the 
nuclei. (F) Low power magnifi  cation of splenic lymphoma, Id+λ2 L chain 
(red, 2B6 mAb) versus κ (green). (inset) Large Id+ lymphoma cell com-
pared with smaller κ+ B cell. (G) Id-specifi  c T cells (red, TCR clonotype-
specifi  c mAb GB113) and lymphoma cells (green, 2B6 mAb) were often in 
close contact (yellow). See inset for higher magnifi  cation of a synapse.1184  ID-DRIVEN LYMPHOMAGENESIS | Zangani et al.
Id-specifi  c T cells collaborate with Id+ lymphoma in vitro 
and in vivo
As suggested by the phenotype analysis above, Id+ lymphoma 
cells were excellent stimulators of both naive and memory 
Id-specifi  c T cells in vitro (Fig. 4 A and not depicted). Vice 
versa, both naive and memory Id-specifi  c T cells stimulated 
the proliferation of the CD40+ Id+ lymphoma cells. The 
  bidirectional collaboration between B lymphoma cells and 
T cells was direct and did not require other cells (Fig. 4 B 
and not depicted). Collaboration was completely inhibited 
by a combination of antibodies to MHC class II and costimu-
latory molecules (Fig. 4 C).
Consistent with the bidirectional stimulation observed 
in vitro, lymphoma tissue was infi  ltrated by Id-specifi  c T cells 
that were activated (CD69+) and greatly increased in numbers 
compared with controls (Fig. 5, A–C). Moreover, histological 
sections revealed that infi  ltrating Id-specifi  c T cells were fre-
quently in synapse with lymphoma cells, indicating ongoing 
collaboration in vivo (Fig. 2 G). Note that Id-specifi  c T cells 
were only expanded in lymphoma-bearing mice, but not in 
Th2-injected Id+ littermates that did not develop lymphomas 
(Fig. 5, A and B). This fi  nding demonstrated prolonged mutual 
expansion of paired B and T cells exclusively in the mice that 
had undergone lymphomagenesis.
Id+ lymphoma eventually expand autonomously, 
independent of T cells
It was of interest whether B lymphomas maintained a reliance 
on Id-specifi  c T cells for their growth. To test this, lymphoma 
cells were transferred to recipient animals. After only two 
transfers, hardly any Id-specifi  c CD4+ T cells were detectable 
in lymphomas of recipients, suggesting that Id+ lymphomas 
had become independent of T cells (Fig. 5 D). In fact, signs 
of T cell independency were sometimes found already in the 
original lymphoma mice because lymphoma tissue in kidneys 
were sometimes devoid of Id-specifi  c T cells (Fig. S3).
Lymphoma development and reemergence of Id-specifi  c 
T cells could be monitored in the blood during 
the latency period
We have previously described that Id-specifi  c Th2 cells 
  injected into Id+ mice trigger short-term B cell proliferation, 
germinal center formation, extra follicular B cell diff  erentiation, 
and plasma cell diff  erentiation (23). Here, we demonstrate 
that injected Th2 cells also activate marginal zone B precursors 
and marginal zone B cells (Fig. S5, available at http://www
.jem.org/cgi/content/full/jem.20061220/DC1). However, 
Figure 3.  Id+ B cell lymphomas resemble late marginal zone pre-
cursor B cells and highly express the Id+ L chain and molecules in-
volved in cognate interaction with T cells. Lymphomatous spleen cells 
were transferred to RAG2−/− mice that developed disease within 6–8 wk. 
Gated CD19+ lymphoma cells and BALB/c B cells were compared for 
CD21 versus CD23 (staining of spleen cells; A), IgM and IgD (spleen cells; 
B and C), CD1d, CD38, and AA4.1 (spleen cells; C), CD138 versus Fsc (CD19+ 
liver cells; D), and CD131 (IL-3R β chain) versus CD123 (IL-3R α chain; E) 
spleen cells. (F) Proliferation of cultured lymphoma line cells in the presence 
of cytokines (5 ng/ml), measured as incorporation of 3HTdR. The y axis shows 
time change in cpm compared with proliferation in absence of cytokines, 
normalized to 1. (G and H) Expression of molecules related to T–B 
collaboration. (G) Gated B220+ splenocytes from Id-Th2®Id+ mouse with 
lymphoma (thick line) were compared with Id+ mice (dashed line). (fi  lled 
histogram) Isotype-matched control. (H) Id+ L chain expression on CD19+ 
splenocytes in Id-Th2®Id+ mice with B lymphoma compared with Ova-
Th2®Id+ mice. The numbers in the quadrants indicate percentages.JEM VOL. 204, May 14, 2007  1185
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consistent with previous results (10, 23), Id-driven T–B col-
laboration waned within 7 wk after last T cell transfer, at 
which time point mice had essentially normal B cell popula-
tions and very few Id-specifi  c T cells (< 1%).
It was of interest to detect early signs of lymphoma de-
velop  ment during the latency period. However, it is prob-
lematic to approach this issue because even if a killed mouse 
was found to have suspicious changes, we could not be cer-
tain if the very same mouse eventually would have developed 
clinical lymphoma. To circumvent this problem, we resorted 
to repeated staining of blood lymphocytes during the   latency 
  period. Six Id+ mice injected eight times with Id-specifi  c 
Th2 cells were followed. Although increased numbers of 
Id+IgM+BrdU+CD69+ blasts were found in the blood within 
the fi  rst 35 d after the last T cell transfer, such supposedly 
polyclonally activated B cells had disappeared by day 50 (Fig. 
S6, available at http://www.jem.org/cgi/content/full/jem
.20061220/DC1, and not depicted). However, after another 
50 d, two out of the three mice that several months later 
  developed lymphomas had a striking increase in IdHiIgMHi
CD69− large blasts (Fig. S6). The same two mice also had 
an increase in Id-specifi  c CD4+ T cells. Thus, occurrence 
of lymphoma-like B cells and Id-specifi  c T cells in blood cor-
related signifi  cantly (P < 0.001) and heralded later lymphoma 
development (Fig. S6).
Id+ lymphoma were biclonal/monoclonal 
in terms of variable heavy chain (VH) gene usage 
and expressed few mutations
Id+ mice have a polyclonal heavy (H) chain repertoire (21, 
23, 28). Thus, even though the lymphomas all expressed the 
transgenic Id+ L chain, each lymphoma should express distinct 
H chains that could serve as a clonal marker. We therefore 
analyzed the VDJ sequence repertoires in two lymphoma mice 
and their recipients. In one mouse, the sequences obtained 
from the spleen, liver, and kidney were nearly monoclonal, 
and this signature was conserved over the course of four con-
secutive transfers (Fig. 6 and Fig. S7, available at http://www
.jem.org/cgi/content/full/jem.20061220/DC1). The second 
Figure 4.  Id+ B cell lymphomas bidirectionally collaborate with 
Id-specifi  c T cells. (A) Proliferation of naive Id-specifi  c TCR transgenic LN 
cells (105/well) in response to the indicated numbers of irradiated (    ) 
B lymphoma cells. (B) Proliferation of an in vitro line of B lymphoma cells 
Figure 5.  Id-specifi  c CD4+ T cells in lymphomatous tissue. (A) CD4+ 
cells were gated from spleens of lymphoma mice and control mice (indi-
cated above plots) and analyzed for expression of the Id-specifi  c TCR 
(GB113 mAb) versus TCRVβ8. The anti-TCRVβ8 (F23.1) mAb stains the 
trangenic β chain of both Id- and ovalbumin-specifi  c T cells, as well as 
Vβ8+ T cells in the Id+ recipients. Id-specifi  c T cells are indicated by the 
arrow. (B) Numbers of Id-specifi  c CD4+ T cells in spleens of indicated 
mice (n = 4/group). (C) CD69 expression on splenic CD4+ Id-specifi  c 
T cells (TCRVβ8+GB113+) from a Th2®Id+ mouse (thick line) compared 
with CD4+TCRVβ8+ T cells in an Ova-Th2®Id+ mouse (fi  lled). (D) Number 
of CD4+ Id-specifi  c T cells in spleens of original lymphoma mice and in 
consecutive recipients after transfers (n = 3–5).
(B Lym) in response to irradiated (    ) T cells. (C) Inhibitory effect of the 
indicated mAbs on proliferation of B lymphoma line induced by irradiated 
Id-specifi  c Th2 cells (  Id-Th2).1186  ID-DRIVEN LYMPHOMAGENESIS | Zangani et al.
lymphoma mouse had a monoclonal VDJ admixed (1:4) with 
a polyclonal VH repertoire (see sequence information in Fig. 6 
for the dominant clone). The polyclonality could clearly be 
seen in a Southern analysis detecting VDJ rearrangements 
(Fig. S11). Upon transfer, lymphoma sequences had a   biclonal 
pattern, the original clone maintaining dominance (Figs. 
S8–S10). Consistent with biclonality, two distinct clonal re-
arrangements were detected by Southern analysis. One of the 
bands appeared to correspond to one of the two lymphoma 
clones defi  ned by sequencing (Figs. S9–S11). Isotype-switch 
variants, as well as a low level of somatic mutations, were 
found in both of the original lymphoma mice (Fig. 6). Inter-
estingly, with transfers and concomitant loss of Id-specifi  c 
T cells, unmutated sequences with μ constant regions gained 
dominance (Fig. 6).
The Id+ lymphoma had major cytogenetic aberrations 
in genomic DNA detected by microarray comparative 
genomic hybridization (CGH)
We used high-resolution oligonucleotide-based microarray 
CGH to investigate whether lymphomas contained genomic 
aberrations. Although the technique does not give exact infor-
mation on particular translocations that may exist in the mouse 
lymphomas, array CGH allows high-resolution analyses of 
DNA copy number aberrations genome-wide (29). Interest-
ingly, all of the six independent lymphomas gained chromo-
somal material and half of them showed gain of whole 
chromosomes (Fig. S12 and S13, available at http://www
.jem.org/cgi/content/full/jem.20061220/DC1). Deletions were 
less extensive and more focal, but some recurrent alterations 
were found (Fig. S13). Aberrations in copy number included 
genes for regulation of transcription, signaling pathways, cell 
cycle and division, as well as apoptosis. Several aberrations 
were shared by three to fi  ve of the six lymphomas (Fig. S13), 
and some minor chromosomal segments were overrepresented 
in high copy number (>10; not depicted).
The Id+ lymphoma can be rejected by Id-specifi  c 
T cells in vivo
Although Id+ lymphomas were induced by injection of Id-
specifi  c Th2 cells, they could nevertheless be susceptible to 
T cell immunosurveillance mediated by the infl  ammatory 
CD4+ Th1 cell subset previously suggested by us to mediate 
rejection of Id+ B lymphomas and myelomas (30, 31). To test 
this, Id+ lymphomas (1.25 × 106) were injected s.c. into Id-
  specifi  c TCR transgenic SCID mice (that only have Id-specifi  c 
Figure 6.  Clonal evolution of B lymphomas as indicated by analysis 
of VDJH sequences. Two lymphoma-bearing mice, X and Y, were 
analyzed, as well as recipients (R1, R2, R3, and R4) of serially transferred 
splenic lymphoma cells (the X and Y lymphomas were also analyzed by 
CGH [Figs. S12 and S13] and by Southern blots using a JH probe [Fig. S11]). 
(A) Repeatedly isolated VDJH lymphoma sequences. Mouse X expressed an 
≈90% (14/15) recurrent VDJ sequence, with identical junctions (dots, 
identical; dashes, nonexisting; N, nontemplate; P, palindromic nucleotides). 
Mouse Y expressed an ≈20% (4/23) repetitive sequence admixed with a 
polyclonal VH repertoire. (B) Lymphoma sequences, mutations, and isotype 
switches are summarized for mouse X and its recipients (left) and for Y and 
its recipients (right). Sequences with identical VDJ junctions were divided 
into “mutated” and “unmutated” as indicated. Each of these categories 
was further classifi  ed according to H chain isotype. Each identical 
sequence with the same H chain is represented as a pie chart. The shade 
of cake segments indicates organ derivation: spleen (black), liver (gray), 
and kidney (white). The digits indicate the number of identical sequences 
obtained from each tissue. For mutated sequences, substitutions (S) and 
their number and insertions (Ins) and their number are given. For recipients 
of mouse Y, a minor additional clone emerged in R2. See Figs. S7–S10 for 
complete compilations of sequences. Online supplemental fi  gures are 
available at http://www.jem.org/cgi/content/full/jem.20061220/DC1.JEM VOL. 204, May 14, 2007  1187
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CD4+ T cells and no CD8+ or B cells). SCID mice served as 
controls. Strikingly, no lymphomas were observed in the chal-
lenged TCR transgenic mice, whereas all SCID mice devel-
oped tumors (Fig. 7), clearly demonstrating the cytotoxicity of 
Id-specifi  c CD4+ T cells against the Id+ lymphoma cells.
D  I  S  C  U  S  S  I  O  N 
Previous papers have suggested that chronic antigenic sti-
mulation of B cells by a variety of mechanisms can induce 
B lymphomas (2–6, 32–34). In the case of non-Hodgkin’s 
lymphoma associated with hepatitis C, the envelope protein 
E2 cross-links CD81 thereby chronically activating naive B cells 
in a polyclonal manner (32). In mucosa-associated lymphoid 
tissue lymphomas associated with Helicobacter pylori gastritis, 
rheumatoid factor B lymphoma precursors have been sug-
gested to receive chronic stimulation via immune complexes 
and toll-like receptors (33, 34). In a mouse model, we describe 
a novel mechanism for lymphomagenesis, which entails two 
salient features, (a) constitutive MHC class II–restricted pre-
sentation of Id peptides by B cells and (b) chronic help deliv-
ered by Id-specifi  c Th2 cells. The large B cell lymphomas 
displayed chromosomal abnormalities, high amounts of the 
Id+Ig L chain, MHC class II molecules, and costimulatory 
CD80/86 and CD40 molecules, and collaborated bidirec-
tionally with Id-specifi  c T cells. Moreover, the lymphoma cells 
and T cells were found in close contact in lymphoma tissue. 
These results suggest that chronic Id-driven T–B collaboration 
could represent a novel mechanism for lymphomagenesis.
The lymphomagenesis apparently started out as a poly-
clonal proliferation of Id+ B cell that later contracted into 
monoclonal/biclonal lymphomas that eventually gained T cell 
independence. During this process, lymphoma microhetero-
geneity, manifested as IgG isotype-switched variants and low 
levels of somatic mutation, was lost. It might be that the micro-
heterogeneity seen in initial stages of lymphoma development 
could depend on Id-specifi  c T cells. Moreover, in the absence 
of T cells, B lymphoma founder cells (IgM+ and unmutated 
VH) might have a growth advantage. Based on these fi  ndings, 
we would like to suggest a model where Id-specifi  c Th2 cells 
induce extensive proliferation of Id+ B cells, rendering them 
vulnerable to the accumulation of oncogenic mutations.
Although most surface markers of the lymphoma indi-
cated a marginal zone origin (CD9+CD1dHiCD38Hi IgMHiC
D5−CD23−CD21HiBCL6−), some markers did not fi  t with 
normal marginal zone B cells (35, 36) or marginal zone lym-
phomas (25–27). More specifi  cally, most lymphomas were 
IgDHi and about half expressed low levels of the transitional 
B cell marker AA4.1. This phenotype is most compatible 
with a putative intermediate between marginal zone precursor 
B cells and marginal zone B cells (see summary of surface 
markers in Fig. S14, available at http://www.jem.org/cgi/
content/full/jem.20061220/DC1). In addition, we demonstrate 
that the lymphoma cells express the IL-3 receptor (as do 
marginal zone B cell precursors). Consistent with this, lym-
phoma cells proliferated in response to IL-3. Some plasmacytoid 
diff  erentiation of the lymphomas was seen, especially with 
time, indicating a degree of terminal diff  erentiation. In this 
regard, it has been demonstrated that marginal zone B cells 
are intrinsically capable of very rapidly maturing into plasma 
blasts (35, 36).
Why did the lymphomas have a late marginal zone pre-
cursor phenotype? First, it has been described that expression 
of the particular Id+λ2315 L chain in transgenic mice selects 
against progression into the follicular B cell compartment, thus, 
the marginal zone B cell compartment is overrepresented in 
these mice (37, 38). As a possible explanation, the λ2315 L 
chain might be poorly compatible with BCR specifi  cities for 
endogenous antigen required for recruitment into the follic-
ular compartment, as suggested in the BCR strength model 
(36). It has also been reported that marginal zone B cell precur-
sors and B cells express high amounts of costimulatory mole-
cules and are able to stimulate even naive T cells (36, 39). 
Collectively, (a) overrepresentation of Id+ B cells in the marginal 
zone lineage and (b) high stimulatory capacity for Id-specifi  c 
T cells and responsiveness to IL-3 (produced by Th2 cells) 
could both contribute to the particular B lymphoma pheno-
type observed. It should be emphasized that the site of malig-
nant transformation is not known. Although all mice had 
ex  tensive peripheral involvement, lymphoma cells were also 
observed in the bone marrow of originator mice. Thus, we 
have not ruled out the possibility that the lymphomas in fact 
arose in the bone marrow and thereafter populated the spleen 
and LN with intact AA4.1 and IL-3 receptor expression as signs 
of recent bone marrow emigration. Because of this ambiguity, 
it is diffi   cult to classify the lymphoma according to stages 
  described for marginal zone lymphomas in mice (25, 26).
There is previous circumstantial evidence that supports 
a role for T cells in B cell lymphomagenesis. First, T cell in-
fi  ltrates are a common feature of both Hodgkin’s and non-
Hodgkin’s B cell lymphomas (2, 4–6). Second, lymphoma cells 
attract T cells (including Th2 cells) by secreting chemokines 
(40, 41). Third, human follicular B lymphoma cells often ex-
press CD40, ligation of which may facilitate their growth (42). 
Figure 7.  Th2-induced B lymphomas are rejected by TCR trans-
genic SCID mice. Id+ lymphoma cells (1.25 × 106) were injected into 
Id-specifi  c TCR transgenic SCID mice or SCID mice (n = 5/group) and 
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Thus, in EBV-associated lymphomagenesis in SCID-Hu 
models, T cells as well as CD40 ligation were required (43, 44). 
Fourth, follicular lymphoma cells were helped in vitro by al-
loreactive T cells in a cell contact–dependent manner (45). Fifth, 
in Bcl-2 trangenic mice, germinal center hyperplasia and 
eventual B lymphoma development was dependent on CD4+ 
T cells of unknown specifi  city (46). The present fi  ndings ex-
tend these previous observations by directly demonstrating 
that Id-specifi  c Th2 cells can induce lymphomas by chronic 
cognate interaction with Id+ B cells. The results suggest that 
cognate Th2–B cell collaboration could be lymphomagenic 
also when B cells chronically present other endogenous anti-
gens like viral peptides to Th2 cells.
It is well known that autoimmune diseases like rheuma-
toid arthritis and systemic lupus erythematosus predispose 
for B lymphoma development (2, 3). It is therefore interest-
ing to note that transfer of Id-specifi  c Th2 cells into Id+ 
mice fi  rst induces a transient production of autoantibodies 
(23, 24) and, only later, B lymphomas. Thus, Id-driven T–B 
collaboration might possibly represent a mechanism that 
explains the epidemiological link between autoimmunity and 
B lymphoma development.
It is surprising that Id-specifi  c Th2 cells in the present 
  experiments caused lymphomas because T cells are currently 
believed to eliminate rather than induce cancers. In fact, 
cancer cells have been suggested to be phenotypically sculpted 
by T cells in a process called immunoediting (47). The latter 
paradigm certainly applies to cytotoxic CD8+ and infl  ammatory 
CD4+ Th1 cells (47). As concerns Th2 cells, they have pre-
viously been reported to protect mice against ovalbumin-
transfected lymphoma cells (48). However, those tumor-
challenge experiments (48) were rather diff  erent from the 
present, where the continuous presence of Id-specifi  c Th2 cells 
over many months induced Id+ B lymphomas, selected for 
ability to bidirectionally collaborate with the injected Th2 cells. 
We would therefore like to suggest that tumor-associated 
Th2 cells may initially nurture B lymphoma cells in a symbiotic 
relationship that we call T cell–dependent lymphomagenesis. 
Whether this process involves a selection of preexisting Th2 
and B cells, or long-term mutual shaping events that facilitate 
potent interaction, remains to be determined.
It should be stressed that even with these Th2-induced 
lymphomas, immunosurveillance still operates because the lym-
phomas were promptly rejected when injected into Id-specifi  c 
TCR-transgenic SCID mice, most likely caused by generation 
of cytotoxic Th1 cells (30). Thus, Id-specifi  c CD4+ T cells with 
an identical TCR appear capable of either inducing or eradi-
cating lymphoma cells, depending on T cell phenotype and 
the experimental situation.
Because few normal individuals develop lymphomas,   severe 
constraints (a–e) must operate on Id-driven T–B collaboration 
and lymphoma development. (a) Id peptides must have the 
ability to bind MHC class II molecules of the individual. (b) 
T cells are tolerant to germline-encoded Id peptides and can 
only respond to rare Id peptides that express somatic muta-
tions or N region diversity (16–18). (c) Id+ B and Id-specifi  c 
T cells are both infrequent, reducing the chance that matched 
cells encounter each other during lymphocyte recirculation 
(17–19, 23). (d) Id-dependent T–B collaboration could be con-
trolled by peripheral tolerance mechanisms (49–51). (e) The 
accumulation of secondary genetic changes required for B lym-
phoma development might be quite rare.
Some previous observations could, if reinterpreted, support 
a role for Id-driven T–B collaboration in B cell   tumorigenesis 
in patients (52–55). Thus, Id-specifi  c CD4+ T cells have pre-
viously been described in a B lymphoma patient (52), in B cell 
chronic lymphocytic leukemia patients (53), as well as in 
patients with monoclonal gammopathy of unknown signifi  -
cance (54) or multiple myeloma (55). In these cases, Id-specifi  c 
T cells have been considered to fi  ght the tumor. The present 
results suggest an alternative explanation, i.e., that Id-specifi  c 
T cells could rather have promoted tumor development in 
these patients. Clearly, further studies on the dichotomous 
lymphomagenic versus lymphomatoxic potential of Id-specifi  c 
CD4+ subsets (Th1 and Th2) are needed. This issue is partic-
ularly relevant to Id vaccination of patients, which conceivably 
could result in expansion of Id-specifi  c T cells with tumor-
enhancing instead of tumor-eradicating properties.
MATERIALS AND METHODS
Mice. Mice transgenic for the λ2315 Ig L chain (Id+ mice; reference 21) were 
on a BALB/c background. Off  spring from BALB/c × hemizygous Id+ mice 
were used, with the transgene-negative littermates serving as negative controls. 
Id-specifi  c TCR transgenic mice (17) were on a C.B-17 scid/scid background. 
BALB/c, BALB/c RAG2−/−, and C57BL/6 RAG2−/− mice were obtained 
from Taconic M&B. Ovalbumin-specifi  c DO.11.10 TCR transgenic mice 
were purchased from JaxMice. All experiments were approved by the 
Norwegian Animal Research Committee.
Induction and transfer of lymphomas. Short-term cultured polarized 
Th2 cell lines were generated from Id-specifi  c TCR transgenic SCID or 
  ovalbumin-specifi  c TCR transgenic mice as described previously (23), and 
5 × 106 cells were injected i.v. every 10th day the indicated number of 
times into Id+ or Id− littermates, starting at 6 wk of age. Mice were monitored 
for >250 d. The following signs of pathology were monitored: abdominal 
distension, lethargy, anemia, and weight loss. Splenic Id+ lymphomas were 
further transferred into recipients (RAG2−/− BALB/c [H-2d] or RAG2−/− 
C57BL/6 [H-2b]). In some experiments, BrdU was provided as an i.p. injection 
(1 mg) 2 d before analysis.
Antibodies and fl  ow cytometry. The following mAbs were affi   nity 
purifi  ed and biotinylated or FITC conjugated in our laboratory: transgenic 
TCR clonotype–specifi  c GB113 (17), anti–MHC class II (TIB-120 and 
M5/114.15.2; American Type Culture Collection), 2B6 (anti-Cλ2/3), and 
anti-κ (187.1). The following antibodies (FITC, phycoerythrin, biotinylated, 
or allophycocyanin conjugated) were purchased from BD Biosciences: anti-
CD1d (1B1), anti-CD4 (RM4-5), anti-CD5 (53-7.3), anti-CD8 (53-6.7), 
anti-CD9 (KMC8), anti-CD11b (M1/70), anti-CD19 (1D3), anti-CD21/
CD35 (7G6), anti-CD23 (B3B4), anti-CD38 (90), anti-CD40 (3/23), anti-
CD45R/B220 (RA3-6B2), anti-CD69 (H1.2F3), anti-CD80 (16-10A1), 
anti-CD86 (GL1) anti-CD138 (281–2), anti-CD123 (5B11), anti-CD131 
(JORO50), Ly-6G [Gr-1] (RB6-875), anti-TCRVβ8 (F23.1), anti-IgMa 
(DS-1), anti-IgD (11-26c.2a), anti-immature B cells (AA4.1, anti-C1qRp/
CD93), and anti-BrdU (Becton Dickinson). Streptavidin-Cy-chrome and 
streptavidin-peridinin chlorophyll-a protein (SAv-PerCP) were purchased 
from BD Biosciences. Quadruple stainings were performed with FITC-, 
PE-, PerCP-, and APC-conjugated mAbs and acquired on a FACS Calibur JEM VOL. 204, May 14, 2007  1189
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(Becton Dickinson), and fi  les were analyzed with CellQuest Pro (BD 
Biosciences) and WinMDI 2.7.
B Lymphoma cell and T cell proliferation assays. Both day 30–cultured 
lymphoma cell lines and lymphoma cells taken directly ex vivo were tested. 
Proliferation of B lymphoma cells (5 × 104/well) in response to Id-specifi  c 
T cells (5 × 104/well) was measured by culturing B cells with irradiated 
T cells (1,000 rad), with a 3H-TdR overnight pulse from day 2 to 3, as 
  described previously (23). Conversely, lymphoma cells were irradiated and 
T cell proliferation was measured. Lymphoma cell proliferation was assayed 
in the presence of tittered concentrations of anti–MHC class II (TIB-120), 
anti-CD80, and anti-CD86 mAbs. Recombinant cytokines were obtained 
from BD Biosciences.
Immunohistochemistry. Organs were imbedded in OCT (Tissue-Tek). 
5-μm frozen sections were mounted on l-polylysine–coated glass slides, air 
dried overnight, blocked with 30% heat-aggregated rat serum, stained with 
biotinylated or FITC-conjugated mAbs (see Antibodies and fl  ow cytometry 
section) and streptavidin-Cy2 and 3 (GE Healthcare), and counterstained 
with DAPI (Invitrogen). 5-μm-thick formalin-fi  xed, paraffi   n-embedded 
  tissue sections were rehydrated and stained. In brief, slides were soaked in 
xylene, passed through graded alcohols, and put in distilled water. Slides 
were then pretreated with 10 mM citrate, pH 6.0 (CD3, B220, and BCL-6), 
or 1.0 mM EDTA, pH 8.0 (CD138 and MUM1/IRF-4; Zymed Laboratories), 
in a steam pressure cooker (Decloaking Chamber; BioCare Medical) as per the 
manufacturer’s instructions and followed by washing in distilled water. All 
further steps were performed at room temperature in a hydrated chamber. Slides 
were next pretreated with peroxidase block (DakoCytomation) for 5 min to 
quench endogenous peroxidase activity. Primary rabbit anti-CD3 antibody 
(DakoCytomation), rat-anti B220 (clone RA3-6B2, BD Biosciences), goat 
anti-MUM1/IRF-4 (M-17; Santa Cruz Biotechnology, Inc.), rabbit anti–
BCL-6 (N-3; Santa Cruz Biotechnology, Inc.), or rat anti-CD138 (clone 
281-2; BD Biosciences) was applied in DakoCytomation diluent for 1 h. For 
B220 and CD138, rabbit anti–rat Ig antibody (DakoCytomation) was applied 
in DakoCytomation diluent for 1 h. Slides were washed in 50 mM Tris-Cl, 
pH 7.4, and detected with anti-rabbit Envision+ kit (CD3, B220, BCL-6, 
and CD138; DakoCytomation) or LSAB+ staining kit (MUM1/IRF-4; 
DakoCytomation) as per the manufacturer’s instructions. After further 
washing, immunoperoxidase staining was developed using a DAB chromogen 
(DakoCytomation) and counterstained with hematoxylin.
Sequencing of lymphoma VH. Variable heavy chains from mouse lym-
phoma tissue (spleen, liver, and kidney) were cloned by the use of degenerate 
FR1 region primers, designed to amplify most VH mouse sequences, together 
with C-region primers (56). The recombinant DNA was sequenced and an-
alyzed for VDJ gene segment usage, somatic mutations, and isotype switch. 
In brief, total RNA was isolated from either mouse lymphoma tissue (spleen, 
liver, and kidney) frozen in OCT compound or from fresh lymphoma tissue 
submerged in RNAlater (Ambion) by use of TRIzol reagent (Invitrogen). 
Reverse transcriptase was performed using a NotI-d(T)18 primer (First-strand 
cDNA synthesis kit; GE Healthcare). cDNA was amplifi  ed by PCR using 
PfuTurbo DNA polymerase (Stratagene) and a mixture of 5′ heavy chain 
FR1-region degeneracy primers together with a mixture of 3′ heavy chain 
constant (C)–region primers without cloning sites (reference 56; Sigma-
  Aldrich). The PCR products were run on a 1.5% agarose gel, and gel-
purifi  ed products of predicted size (≈400 bp; QIAquick gel extraction 
kit; QIAGEN) were ligated into pGEM-T Easy vector (Promega) and used 
to transform JM109 competent cells (Promega). Plasmid DNA was prepared 
from overnight cultures (Wizard plus SV minipreps DNA purifi  cation sSystem; 
Promega), and colonies found to contain an insert were sequenced using T7 
and/or SP6 primer (GATC Biotech AG). At least three colonies were 
sequenced for each case. Sequence alignments were made using the current 
IMGT/V-QUEST (http://imgt.cines.fr) and NCBI/BLAST (http://www
.ncbi.nlm.nih.gov/BLAST/) tools to fi  nd the closest matching germline VDJ 
gene segments. The IMGT/JunctionAnalysis tool was used to identify the 
junctions between the rearranged VDJ gene segments, including N (nontem-
plate) and P (palindromic) nucleotides.
Statistical analysis. In survival analyses, p-values were calculated with the 
Mantel-Haenszel Log rank test. The two-tailed Mann-Whitney test was used 
to calculate p-values when comparing numerical data.
VH sequences. All nucleotide sequences are available from GenBank/
EMBL/DDBJ under accession nos. DQ416684–DQ416716.
Online supplemental material. Figs. S1–S14 provide an additional descrip-
tion of the lymphoma phenotype, cytogenetic abnormalities, lymphoma VDJ 
sequences, IL-3 receptor expression on marginal zone B cells, and marginal 
zone Id+ B cell responses to Id-specifi  c T cells. Online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20061220/DC1.
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